In the Claims:

1. (previously presented) A recombinant human immunodeficiency virus-1 (HIV-1), wherein the natural signal sequence (NSS) of the HIV-1 envelope glycoprotein gp120 of the virus is replaced with a signal sequence selected from the group consisting of mellitin signal sequence (MSS) and interleukin 3 signal sequence (ILSS).

Claims 2-5 (canceled)

- 2 %. (previously presented) The HIV-1 of claim 1 wherein the retrovirus is avirulent.
- (previously presented) The HIV-1 of claim b wherein the retrovirus is rendered avirulent by deletion of the *nef* gene.

Claims 8-30 (canceled)

- 4 31. (previously presented) The HIV-1 of claim 1 wherein the MSS is shown as SEQ ID NO 9.
- (previously presented) The HIV-1 of claim 1 wherein the ILSS is shown as SEQ ID NO 10.
- (previously presented) The HIV-1 of claim 3/1 wherein the retrovirus is avirulent.
- 7 \$\frac{3}{4}\$. (previously presented) The HIV-1 of claim \$\frac{3}{2}\$ wherein the retrovirus is avirulent.
- (previously presented) The HIV-1 of claim 33 wherein the retrovirus is rendered avirulent by deletion of the nef gene.
- 9 36. (previously presented) The HIV-1 of claim 3/3 wherein the retrovirus is rendered avirulent by deletion of the nef gene.
- (currently amended) A vaccine immunogenic composition comprising an effective amount of the HIV-1 of claim 32.
- (currently amended) An vaccine immunogenic composition comprising an effective amount of the HIV-1 of claim 34.
- (currently amended) An vaccine immunogenic composition comprising an effective amount of the HIV-1 of claim 35.8
- (currently amended) An vaccine immunogenic composition comprising an effective amount of the HIV-1 of claim 36.9